Zum Hauptinhalt springen

The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.

Shkreta, L ; Toutant, J ; et al.
In: Oncotarget, Jg. 15 (2024-05-16), S. 313-325
Online academicJournal

Titel:
The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.
Autor/in / Beteiligte Person: Shkreta, L ; Toutant, J ; Delannoy, A ; Durantel, D ; Salvetti, A ; Ehresmann, S ; Sauvageau, M ; Delbrouck, JA ; Gravel-Trudeau, A ; Comeau, C ; Huard, C ; Coulombe-Huntington, J ; Tyers, M ; Grierson, D ; Boudreault, PL ; Chabot, B
Link:
Zeitschrift: Oncotarget, Jg. 15 (2024-05-16), S. 313-325
Veröffentlichung: Albany, N.Y. : Impact Journals, 2024
Medientyp: academicJournal
ISSN: 1949-2553 (electronic)
DOI: 10.18632/oncotarget.28585
Schlagwort:
  • Humans
  • Cell Line, Tumor
  • Antineoplastic Agents pharmacology
  • Protein Serine-Threonine Kinases metabolism
  • Protein Serine-Threonine Kinases genetics
  • Protein Serine-Threonine Kinases antagonists & inhibitors
  • Thiazoles pharmacology
  • Antiviral Agents pharmacology
  • HCT116 Cells
  • DEAD-box RNA Helicases metabolism
  • DEAD-box RNA Helicases genetics
  • Gene Expression Profiling
  • Epithelial-Mesenchymal Transition drug effects
  • Protein-Tyrosine Kinases metabolism
  • Protein-Tyrosine Kinases antagonists & inhibitors
  • Protein-Tyrosine Kinases genetics
  • Protein Kinase Inhibitors pharmacology
  • Cell Proliferation drug effects
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article
  • Language: English
  • [Oncotarget] 2024 May 16; Vol. 15, pp. 313-325. <i>Date of Electronic Publication: </i>2024 May 16.
  • MeSH Terms: Epithelial-Mesenchymal Transition* / drug effects ; Protein-Tyrosine Kinases* / metabolism ; Protein-Tyrosine Kinases* / antagonists & inhibitors ; Protein-Tyrosine Kinases* / genetics ; Protein Kinase Inhibitors* / pharmacology ; Cell Proliferation* / drug effects ; Humans ; Cell Line, Tumor ; Antineoplastic Agents / pharmacology ; Protein Serine-Threonine Kinases / metabolism ; Protein Serine-Threonine Kinases / genetics ; Protein Serine-Threonine Kinases / antagonists & inhibitors ; Thiazoles / pharmacology ; Antiviral Agents / pharmacology ; HCT116 Cells ; DEAD-box RNA Helicases / metabolism ; DEAD-box RNA Helicases / genetics ; Gene Expression Profiling
  • References: Front Oncol. 2023 Jun 05;13:1152087. (PMID: 37342192) ; Oncol Rep. 2015 Sep;34(3):1231-8. (PMID: 26151392) ; EMBO J. 2006 Apr 19;25(8):1730-40. (PMID: 16601681) ; RNA. 2021 Nov;27(11):1302-1317. (PMID: 34315816) ; Oncotarget. 2017 May 2;8(18):29935-29950. (PMID: 28404898) ; Biochem Biophys Res Commun. 2009 Oct 23;388(3):529-32. (PMID: 19666000) ; Br J Cancer. 2021 Jan;124(1):259-269. (PMID: 33299129) ; Mol Oncol. 2018 Oct;12(10):1811-1826. (PMID: 30171795) ; Cell Cycle. 2020 Aug;19(15):1917-1927. (PMID: 32594834) ; PLoS One. 2017 Mar 29;12(3):e0174037. (PMID: 28355289) ; Cancer Lett. 2010 Jul 28;293(2):230-9. (PMID: 20144848) ; Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3287-96. (PMID: 25074920) ; Genome Biol. 2014 Aug 28;15(8):454. (PMID: 25164765) ; Front Pharmacol. 2022 Sep 14;13:935493. (PMID: 36188577) ; EMBO J. 2021 Sep 15;40(18):e108647. (PMID: 34459003) ; Mol Biol Cell. 2024 Feb 1;35(2):ar17. (PMID: 38019605) ; Nat Commun. 2014 Aug 05;5:4581. (PMID: 25091051) ; Nucleic Acids Res. 2017 Apr 20;45(7):4051-4067. (PMID: 27928057) ; Sci Rep. 2021 Apr 12;11(1):7963. (PMID: 33846420) ; Nat Cell Biol. 2012 May 13;14(6):567-74. (PMID: 22581054) ; Exp Cell Res. 2018 Jun 15;367(2):216-221. (PMID: 29608915) ; Mol Cell Biol. 2017 Dec 13;38(1):. (PMID: 29038160) ; Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19204-9. (PMID: 22080605) ; Cancers (Basel). 2020 Aug 06;12(8):. (PMID: 32781579) ; Cell Rep Med. 2024 Feb 20;5(2):101411. (PMID: 38325381) ; Cancer Res. 2011 Mar 15;71(6):2034-7. (PMID: 21406394) ; PLoS Pathog. 2020 Nov 12;16(11):e1008593. (PMID: 33180834) ; Nat Commun. 2022 Mar 16;13(1):1363. (PMID: 35296659) ; Mol Cell. 2020 Apr 2;78(1):57-69.e4. (PMID: 32059760) ; Nat Rev Cancer. 2009 Oct;9(10):701-13. (PMID: 19693097) ; Dev Cell. 2018 Jun 18;45(6):681-695.e4. (PMID: 29920274) ; Life Sci. 2024 Feb 1;338:122392. (PMID: 38160788) ; J Biol Chem. 2004 Feb 6;279(6):4433-9. (PMID: 14634006) ; Nat Commun. 2022 May 19;13(1):2800. (PMID: 35589715) ; PLoS One. 2020 Oct 16;15(10):e0240718. (PMID: 33064779) ; Retrovirology. 2022 Aug 19;19(1):18. (PMID: 35986377) ; Signal Transduct Target Ther. 2021 May 17;6(1):183. (PMID: 33994545) ; Int Immunopharmacol. 2024 Jan 25;127:111376. (PMID: 38113691) ; Oncogene. 2009 Aug 6;28(31):2839-48. (PMID: 19525980) ; NAR Cancer. 2021 May 25;3(2):zcab019. (PMID: 34316707) ; Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) ; Oncotarget. 2019 Aug 20;10(49):5007-5010. (PMID: 31489110) ; Nat Rev Cancer. 2006 Oct;6(10):813-23. (PMID: 16990858) ; Cancer Res. 2013 Aug 1;73(15):4937-49. (PMID: 23733751) ; Mol Cell. 2007 Oct 12;28(1):79-90. (PMID: 17936706) ; J Gastroenterol. 2013 Nov;48(11):1271-82. (PMID: 23354623) ; EMBO Mol Med. 2018 Jun;10(6):. (PMID: 29769258) ; Cancer Lett. 2020 Mar 31;473:186-197. (PMID: 31560935) ; Front Cell Dev Biol. 2017 Mar 07;5:18. (PMID: 28326306) ; Sci Rep. 2020 Sep 7;10(1):14689. (PMID: 32895446) ; Cell Mol Immunol. 2014 Jan;11(1):49-57. (PMID: 24037184) ; Cell. 2021 Jan 21;184(2):384-403.e21. (PMID: 33450205) ; Science. 1998 Sep 4;281(5382):1509-12. (PMID: 9727977) ; Mol Cell. 2020 Sep 3;79(5):846-856.e8. (PMID: 32755594) ; Oncogene. 2019 Mar;38(11):1845-1859. (PMID: 30367150) ; J Med Chem. 2023 Mar 23;66(6):4106-4130. (PMID: 36876904) ; J Mol Cell Biol. 2019 Apr 1;11(4):267-276. (PMID: 30496442) ; J Med Chem. 2016 Mar 10;59(5):1869-79. (PMID: 26878150)
  • Contributed Indexing: Keywords: CLK kinases inhibitors; EMT; antiviral immune response; metastasis; microtubules
  • Substance Nomenclature: 0 (Clk dual-specificity kinases)
  • Entry Date(s): Date Created: 20240516 Date Completed: 20240516 Latest Revision: 20240518
  • Update Code: 20240518
  • PubMed Central ID: PMC11098031

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -